相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
Young Lim Choi et al.
CANCER RESEARCH (2008)
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2008)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
Kentaro Inamura et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sreenath V. Sharma et al.
GENES & DEVELOPMENT (2007)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
Ultan McDermott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
LKB1 modulates lung cancer differentiation and metastasis
Hongbin Ji et al.
NATURE (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
Danan Li et al.
CANCER CELL (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Transforming activity of purinergic receptor P2Y, G-protein coupled, 2 revealed by retroviral expression screening
Hisashi Hatanaka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Identification of a constitutively active mutant of JAK3 by retroviral expression screening
Young Lim Choi et al.
LEUKEMIA RESEARCH (2007)
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Anna V. Galkin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Transforming activity of purinergic receptor P2Y, G protein coupled, 8 revealed by retroviral expression screening
Shin-Ichiro Fujiwara et al.
LEUKEMIA & LYMPHOMA (2007)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice
WR Duan et al.
ONCOGENE (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Interleukin-5-mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice
A Mishra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Transgenic mouse models for lung cancer
BH Zhao et al.
EXPERIMENTAL LUNG RESEARCH (2000)
分享论文
